Despite advances in transfection methods and culture optimization, many CHO-based TGE systems produce insufficient antibody titers (low mg/L level) for full use within biotherapeutic development pipelines. The high productivity of MaxCyte-driven transient gene expression allows for its use in early phase candidate identification as well as for generating the gram-level antibody quantities needed for later stage pharmacology, stability and manufacturing studies.
In this white paper, data are presented demonstrating the reproducibility, scalability and antibody production capabilities of MaxCyte Flow Electroporation™ Technology. Secreted antibody titers routinely exceed 400 mg/L and can exceed 2.7 g/L following minimal process optimization, thereby enabling multi-gram antibody production from a single, CHO cell transfection. In addition, data are presented showing the use of Flow Electroporation Technology for the rapid generation of high-yield stable CHO cell lines to bridge the gap between early- and late-stage antibody development activities.